The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Self-citationDC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
Geijtenbeek, T. B. H., Kwon, D. S., Torensma, R., van Vliet, S. J., van Duijnhoven, G. C. F., Middel, J., Cornelissen, I. L. M. H. A., Nottet, H. S. L. M., KewalRamani, V. N., Littman, D. R., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)80694-7 · Cited by 2,447
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“, was discontinued after causing unforeseen adverse effects in healthy individual”
BackgroundPrevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
Kleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martínez-Martínez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., et al. (2007) · Science · doi:10.1126/science.1144603 · Cited by 975
Self-citationApproval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Cited by
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Eosinophilic Esophagitis in Adults Is Associated With IgG4 and Not Mediated by IgE
Clayton, F., Fang, J. C., Gleich, G. J., Lucendo, A. J., Olalla, J. M., Vinson, L. A., Lowichik, A., Chen, X., Emerson, L., Cox, K., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.05.036 · Cited by 492
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Monoclonal antibody therapeutics: history and future
Buss, N. A., Henderson, S. J., McFarlane, M., Shenton, J. M., & de Haan, L. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.08.001 · Cited by 434
Tau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371
“IgG4 can also split and form heterodimers with other IgG4 antibodies, and it is unclear whether this possibility was considered for the antibodies reviewed above 369,370 .”
BackgroundEfficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Labrijn, A. F., Meesters, J. I., de Goeij, B. E. C. G., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220145110 · Cited by 339
Self-citationWhat is IgG4? A review of the biology of a unique immunoglobulin subtype
Nirula, A., Glaser, S. M., Kalled, S. L., & Taylora, F. R. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283412fd4 · Cited by 309
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
Bispecific antibodies: design, therapy, perspectives
Sedykh, S., Prinz, V., Buneva, V., & Nevinsky, G. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s151282 · Cited by 292
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
Zhang, T., Song, X., Xu, L., Ma, J., Zhang, Y., Gong, W., Zhang, Y., Zhou, X., Wang, Z., Wang, Y., et al. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2160-x · Cited by 290
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
Brennan, F. R., Morton, L. D., Spindeldreher, S., Kiessling, A., Allenspach, R., Hey, A., Müller, P., Frings, W., & Sims, J. (2010) · mAbs · doi:10.4161/mabs.2.3.11782 · Cited by 250
“IgG 4 has an instability in the hinge region that results in the production of half-antibodies (10–30% of the total) both in vitro and in vivo, as observed with natalizumab.(48) These half-antibodies need to be monitored, controlled and characterized because the half-antibodies can exchange their Fab arms with endogen…”
BackgroundGusarova, V., Alexa, C. A., Wang, Y., Rafique, A., Kim, J. H., Buckler, D., Mintah, I. J., Shihanian, L. M., Cohen, J. C., Hobbs, H. H., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054890 · Cited by 210
The clinical significance of allergen-specific IgG4 in allergic diseases
Qin, L., Tang, L.-F., Cheng, L., & Wang, H.-Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032909 · Cited by 71
Feigin, A., Evans, E. E., Fisher, T. L., Leonard, J. E., Smith, E. S., Reader, A., Mishra, V., Manber, R., Walters, K. A., Kowarski, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01919-8 · Cited by 67
Metadata
- Authors
- Labrijn, A. F., Buijsse, A. O., van den Bremer, E. T. J., Verwilligen, A. Y. W., Bleeker, W. K., Thorpe, S. J., Killestein, J., Polman, C. H., Aalberse, R. C., Schuurman, J., van de Winkel, J. G. J., & Parren, P. W. H. I.
- Venue
- Nature Biotechnology
- Published
- 2009-07-20
- Volume
- 27
- Issue
- 8
- Pages
- 767-771
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2038319340
- Cited by
- 298
- References
- 24
- FWCI
- 13.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.